In this webinar designed for patients and caregivers, two cancer survivors share their experiences receiving immunotherapy and answer viewer questions.
Dr. James P. Allison of MD Anderson discusses how some proteins in immune cells act as "brakes" on the immune system response and how checkpoint inhibitors can be used to “release the brakes,” allowing a stronger immune attack against cancer.
Dr. Jedd D. Wolchok of Memorial Sloan Kettering Cancer Center discusses the latest developments in patient care including: checkpoint blockade, cancer vaccines, combination therapies, CAR T cell therapy, T cell receptor therapies, and neoantigens.
Dr. John B. Liao of the University of Washington discusses the immunotherapy landscape for patients with ovarian cancer.
Dr. Dustin A. Deming of the University of Wisconsin Carbone Cancer Center discusses the most effective immunotherapies currently available to patients with stomach, gastrointestinal (GI), and colorectal (CRC) cancers.
Dr. Robert D. Schreiber of of Washington University School of Medicine in St. Louis discusses how advances in our understanding of genomics have enabled doctors to identify the mutations driving individual tumors.
Dr. Hearn Jay Cho of the Mt. Sinai School of Medicine discusses the latest research and developments in cancer immunotherapy for leukemia, lymphoma, and multiple myeloma.
Dr. Haidong Dong of the Mayo Clinic discusses the role biomarkers play in making treatment decisions and delves into the latest research to identify new biomarkers.
Dr. Marie Bleakley of the University of Washington School of Medicine and Seattle Children's Hospital discusses the latest research and developments in immunotherapy for childhood (pediatric) cancers.
In this webinar designed for patients and caregivers, three cancer survivors share their experiences receiving immunotherapy in clinical trials and answer viewer questions.
Dr. Arjun Balar of the NYU Langone Medical Center in New York, NY, discusses the latest research and developments in bladder cancer immunotherapy.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Immunotherapy tripled the median progression-free survival rate among lung cancer patients compared to those who received only chemotherapy and radiation
We introduce you to Thomas Hudson, M.D., vice president, head of oncology discovery and early development at AbbVie.